Current therapies aim to improve insulin resistance (metformin), enhance pancreatic insulin output (meglitinides, sulfonylureas, GLP-1 analogs), or prevent reabsorption of glucose into the blood through the kidneys (SGLT2 inhibitors). This evidence concerns the gene GLP1R and Insulin resistance.